Refractory melanoma patients responded in the landmark 2021 trials
2021
First human evidence that this can overcome checkpoint resistance
3+ yrs
Administering the screened, regulated product in cancer patients
Adjunct
Never a replacement for cancer treatment
In plain terms
What this procedure is, without the jargon.
Unlike the other procedures, this one isn’t an ablation or an injection into the tumor — and importantly, FMT (fecal microbiota transplantation) is not a cancer treatment itself. It is an investigational way to reshape the gut microbiome, the community of bacteria in your intestines, because the microbiome is one of the strongest predictors of whether immunotherapy works.
The aim is to make the immune system more responsive to the immunotherapy that is doing the actual anti-tumor work — not to treat the cancer directly. The strongest human evidence is in melanoma that had stopped responding to anti-PD-1 immunotherapy, where donor FMT plus re-inducing the same immunotherapy produced responses in 3 of 10 treated patients — and in 3 of the 5 who received the transplant itself.
Being honest about the limits: no FMT product is approved for any cancer. The approved products are for a recurrent gut infection, not cancer, and a 2019 federal safety alert flagged a fatal infection from inadequately screened donor stool — so careful screening matters, especially for patients on immunotherapy. We prefer the tightly screened, regulated product and have administered it safely in cancer patients for over three years.
Microbiome conditioning: reshaping the gut so the immunotherapy lands the way it should.
The treated tumor teaches your immune system to recognize the cancer body-wide.
How it works
How this fits into treatment.
Mechanism
The gut-immune axis
Gut bacteria shape anti-tumor immunity through dendritic-cell maturation, IL-12 signaling, interferon-producing T cells and increased CD8+ T-cell activity — making the tumor microenvironment more permissive to checkpoint blockade. This is established in foundational Science papers from 2015 to 2018.
Sequencing
Timed near the immunotherapy window
The direct human evidence times FMT near checkpoint-inhibitor initiation or rechallenge, so we sequence it near the immunotherapy window rather than as a standalone event. Minimizing non-essential antibiotics around that window is biologically plausible but requires clinical judgment.
What makes it different
How this differs from standard FMT.
Standard approaches
Our approach
Most centers offer FMT only for recurrent C. difficile infection.
Microbiome conditioning to support immunotherapy responseas an adjunct to checkpoint and intratumoral treatment.
Stool-bank donor with safety screening only.
Screening that may include immunotherapy-response phenotypefollowing the melanoma trial precedent.
A standalone procedure.
Sequenced near the immunotherapy windowwhere the human evidence places it.
What the evidence shows.
Mechanism is well established
Multiple Science papers between 2015 and 2018 established how specific gut bacteria change the response to checkpoint immunotherapy.
Strongest in refractory melanoma
Two landmark 2021 trials showed donor FMT plus anti-PD-1 rechallenge induced responses in a subset of patients whose disease had stopped responding.
Still investigational
No randomized phase III trial establishes FMT as standard of care for any cancer. We treat it as an adjunct under clinician review, not a therapy in its own right.
Is this right for you
When this may be considered.
This procedure is considered for:
✓Melanoma that has stopped responding to anti-PD-1 immunotherapy — the strongest direct human evidence
✓Lung and kidney cancer, where microbiome-response associations are strong but interventional data is thinner
✓Other solid tumors — investigational and hypothesis-generating only
✓Patients on checkpoint-based or intratumoral immunotherapy where microbiome conditioning is being considered to improve response
